Co-prescribing Viibryd (Vilazodone) with Strattera (Atomoxetine)
Yes, Viibryd and Strattera can be safely co-prescribed together, as there are no direct pharmacokinetic interactions or contraindications between these medications, though monitoring for serotonin syndrome and cardiovascular effects is essential.
Pharmacokinetic Compatibility
The combination is pharmacologically feasible because:
- Atomoxetine is primarily metabolized by CYP2D6 (not CYP3A4), forming 4-hydroxyatomoxetine as its primary metabolite 1
- Vilazodone is metabolized by CYP3A4, with no significant involvement of CYP2D6 2
- No direct metabolic competition exists between these two agents, eliminating concerns about altered drug levels through enzyme inhibition or induction 1
Rationale for Combination Therapy
This combination addresses two distinct therapeutic targets:
- Atomoxetine provides norepinephrine reuptake inhibition for ADHD symptoms (inattention, hyperactivity/impulsivity) 3
- Vilazodone combines serotonin reuptake inhibition with 5-HT1A partial agonism for major depressive disorder 4, 5
- The combination follows established principles for treating comorbid ADHD and depression, where medications targeting different neurotransmitter systems are used for multiple disorders in the same patient 6
Critical Monitoring Requirements
Serotonin Syndrome Risk
- Monitor closely for serotonergic symptoms: agitation, confusion, tachycardia, hypertension, dilated pupils, tremor, hyperreflexia, diaphoresis, hyperthermia, and muscle rigidity 2
- While vilazodone's 5-HT1A partial agonism may theoretically temper excessive serotonergic activity 7, the risk still exists when combining serotonergic agents
- Discontinue both medications immediately if serotonin syndrome develops and initiate supportive treatment 2
Cardiovascular Monitoring
- Atomoxetine causes modest increases in heart rate and blood pressure that are generally well tolerated 3
- Baseline and periodic monitoring of blood pressure and heart rate is recommended, particularly during dose titration 1, 3
- The combination does not increase QT interval prolongation risk 3
Bleeding Risk
- Vilazodone increases bleeding risk when combined with NSAIDs, aspirin, antiplatelet drugs, or anticoagulants 2
- Counsel patients about this risk and monitor for unusual bleeding or bruising
Dosing Recommendations
Vilazodone Dosing
- Start at 10 mg once daily with food for 7 days, then increase to 20 mg daily 2
- Target dose: 20-40 mg once daily with food (food is essential for optimal bioavailability) 2, 4
- Maximum dose: 40 mg daily in the absence of CYP3A4 inhibitors 2
Atomoxetine Dosing
- Dosing depends on CYP2D6 metabolizer status 1
- Extensive metabolizers: Standard dosing with plasma half-life of 5.2 hours 1
- Poor metabolizers: Achieve 10-fold higher steady-state concentrations with half-life of 21.6 hours, though adverse event frequency remains similar 1
- Can be administered once or twice daily 3
Clinical Advantages of This Combination
- No controlled substance concerns: Neither medication carries abuse liability, facilitating long-term prescription management 3
- Complementary mechanisms: Noradrenergic (atomoxetine) and serotonergic (vilazodone) systems are addressed separately 5, 3
- Vilazodone's 5-HT1A partial agonism may reduce the potentiation of stimulant-related gene regulation seen with traditional SSRIs, potentially offering a safer profile in ADHD populations 7
Common Pitfalls to Avoid
- Do not forget food with vilazodone: Bioavailability is significantly reduced without food 2, 4
- Screen for bipolar disorder before initiating vilazodone to avoid precipitating mania/hypomania 2
- Taper vilazodone gradually upon discontinuation to minimize withdrawal symptoms 2
- Do not assume atomoxetine response is universal: 36% of patients discontinue atomoxetine due to GI upset, irritability, or fatigue 8
- Educate patients and families about the treatment plan and obtain informed consent for combination therapy, as recommended for all medication combinations 6